Compounded Tirzepatide Research Guide

Full name: Compounded Tirzepatide (503B Pharmacy)

Compounded tirzepatide offers the most potent dual GLP-1/GIP agonism for weight loss through telemedicine clinics. Provides even greater weight loss efficacy than semaglutide by targeting two incretin pathways simultaneously.

How Compounded Tirzepatide Works

Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss.

Dosing Protocol

• Typical dose: 2.5-15 mg
• Frequency: Once weekly
• Duration: 12-52+ weeks
• Route: Subcutaneous injection

Reported Benefits

• Superior weight loss (20-25%)
• Dual incretin pathway activation
• Better muscle preservation
• Improved A1c
• Cardiovascular protection
• Reduced insulin resistance

Potential Side Effects

• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation
• Injection site reactions

Research Citations

1. SURMOUNT-1 trial (2023) - Tirzepatide 15mg achieved 22.5% mean weight loss at 72 weeks, significantly outperforming semaglutide head-to-head.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Compounded Tirzepatide profile with 3D molecule viewer →